Combination products are where this field is heading, and they are already where part of this market is selling. Those two facts are less related than they look. One of them has a 3,417-person trial behind it; the other has a product page. Telling them apart is worth doing before paying for either, and it is the same discipline as separating a headline from a bill in the headline is not the bill.
What the trial measured
REDEFINE 1 was a 68-week, multicenter, double-blind trial in adults without diabetes who had a BMI of 30 or more, or 27 or more with an obesity-related complication [1]. Participants were randomized in a 21:3:3:7 ratio to the combination of semaglutide 2.4 mg with cagrilintide 2.4 mg, to semaglutide alone, to cagrilintide alone, or to placebo, with lifestyle intervention for everyone.
Among the 3,417 randomized, the estimated mean weight change at week 68 was −20.4% on the combination against −3.0% on placebo, an estimated difference of 17.3 percentage points (95% CI −18.1 to −16.6). Participants on the combination were more likely than those on placebo to reach reductions of 5%, 20%, 25% and 30% or more — thresholds worth reading against the real-world maintenance doses in the dose people actually stay on.
What it cost the people in it
Gastrointestinal adverse events affected 79.6% of the combination group against 39.9% on placebo — nausea, vomiting, diarrhea, constipation or abdominal pain, mainly transient and mild to moderate. Four in five is a high rate even for this drug class, and it is the figure to hold beside the weight result rather than after it. The pattern is the same one described in two-thirds stop within a year.
The combinations that are already for sale
Nothing above is available to buy. What is available, today, on this roster, are compounded products that combine things: two GLP-1 molecules sold in one purchase, and injectable preparations that put vitamins and amino acids in the vial alongside the drug. They carry published prices and no published dose for either component.
No trial has tested any of them. That is not a claim that they are dangerous — it is the narrower and more useful point that the evidence a buyer has seen for semaglutide is evidence about semaglutide, and a vial containing semaglutide plus something else is a different product than the one that was studied. Across the 432 injected semaglutide figures recorded here the median billed rate is $179 a month, read September 2026, and a combination product priced above that is charging a premium for the untested half.
The practical test is the one this site applies everywhere: ask what is in the vial, at what milligram, and what the price does when either number changes. Most sellers here answer none of those, which is counted in nobody says what happens at a higher dose and priced out in what a GLP-1 actually costs.